Appendix to the Consolidated Financial Summary (IFRS) Fiscal 2026 Semi Annual
Filed with TSE · · 9 pages · English
Summary by 6ix AI
This document serves as a supplement to the financial summary disclosed at the Tokyo Stock Exchange, providing detailed financial results and forecasts. It includes information on revenue by regional control function, cash flows, and the status of main products, among other financial metrics. The appendix also outlines the company's research and development pipeline and major applications and approvals as of mid-year.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Kyowa Kirin
- European Commission Approves Crysvita® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union
- FDA Selects Kyowa Kirin for PreCheck Pilot Program to Accelerate Manufacturing Timelines and Enhance Supply Chain Resilience
- New PROSPER Data Demonstrate Real-World Impact of Mogamulizumab on Symptoms and Health-Related Quality of Life in Mycosis Fungoides and Sézary Syndrome
- Kyowa Kirin to Present New Complementary Evidence Further Defining Clinical Utility of Mogamulizumab in Cutaneous T-Cell Lymphoma at 2026 WCCL
- FDA Approves New Dosing Option for CRYSVITA® (burosumab-twza) in Adults With XLH
Later from Kyowa Kirin
- Kyowa Kirin Announces Agreement with U.S. Administration to Reduce Treatment Costs for Americans
- Kyowa Kirin and Knight Therapeutics Enter Into Exclusive Distribution Agreement for POTELIGEO® (mogamulizumab) for Cutaneous T-Cell Lymphoma (CTCL) Patients Across Latin America
- Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab (Poteligeo®) in Patients With Mycosis Fungoides and Sézary Syndrome
- Appendix to the Consolidated Financial Summary (IFRS) Fiscal 2026 Third Quarter
- Consolidated Financial Summary (IFRS) Fiscal 2026 Third Quarter
Follow Kyowa Kirin into a list and get an email when it puts out news.
Follow Kyowa Kirin